Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
Total Valuation
KalVista Pharmaceuticals has a market cap or net worth of $798.13M. The enterprise value is ―.
Market Cap$798.13M
Enterprise Value―
Share Statistics
KalVista Pharmaceuticals has 50,546,290 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding50,546,290
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
KalVista Pharmaceuticals’s return on equity (ROE) is -1.92 and return on invested capital (ROIC) is -91.40%.
Return on Equity (ROE)-1.92
Return on Assets (ROA)-0.73
Return on Invested Capital (ROIC)-91.40%
Return on Capital Employed (ROCE)-0.91
Revenue Per Employee0.00
Profits Per Employee-1.22M
Employee Count150
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of KalVista Pharmaceuticals is ―. KalVista Pharmaceuticals’s PEG ratio is -0.51.
PE Ratio―
PS Ratio0.00
PB Ratio7.17
Price to Fair Value7.17
Price to FCF-4.47
Price to Operating Cash Flow-4.25
PEG Ratio-0.51
Income Statement
In the last 12 months, KalVista Pharmaceuticals had revenue of 0.00 and earned -183.44M in profits. Earnings per share was -3.69.
Revenue0.00
Gross Profit0.00
Operating Income-188.00M
Pretax Income-180.05M
Net Income-183.44M
EBITDA-173.33M
Earnings Per Share (EPS)-3.69
Cash Flow
In the last 12 months, operating cash flow was -167.19M and capital expenditures -175.00K, giving a free cash flow of -167.36M billion.
Operating Cash Flow-167.19M
Free Cash Flow-167.36M
Free Cash Flow per Share-3.31
Dividends & Yields
KalVista Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.88
52-Week Price Change78.82%
50-Day Moving Average13.40
200-Day Moving Average12.99
Relative Strength Index (RSI)57.09
Average Volume (3m)1.45M
Important Dates
KalVista Pharmaceuticals upcoming earnings date is Mar 17, 2026, Before Open (Confirmed).
Last Earnings DateDec 4, 2025
Next Earnings DateMar 17, 2026
Ex-Dividend Date―
Financial Position
KalVista Pharmaceuticals as a current ratio of 5.35, with Debt / Equity ratio of 15.06%
Current Ratio5.35
Quick Ratio5.35
Debt to Market Cap<0.01
Net Debt to EBITDA0.53
Interest Coverage Ratio-32.50
Taxes
In the past 12 months, KalVista Pharmaceuticals has paid 3.39M in taxes.
Income Tax3.39M
Effective Tax Rate-0.02
Enterprise Valuation
KalVista Pharmaceuticals EV to EBITDA ratio is -3.41, with an EV/FCF ratio of -3.87.
EV to Sales0.00
EV to EBITDA-3.41
EV to Free Cash Flow-3.87
EV to Operating Cash Flow-3.87
Balance Sheet
KalVista Pharmaceuticals has $309.16M in cash and marketable securities with $149.59M in debt, giving a net cash position of $159.57M billion.
Cash & Marketable Securities$309.16M
Total Debt$149.59M
Net Cash$159.57M
Net Cash Per Share$3.16
Tangible Book Value Per Share$1.92
Margins
Gross margin is 74.33%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin74.33%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for KalVista Pharmaceuticals is $32.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$32.13
Price Target Upside103.48% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast-13.14%